|
Greg,
You might have read that we were approved for Promacta at NIH, but received the approval AFTER we got our appointment at M. D. Anderson. Then when the blast numbers came back at 10%, that disqualified him. I just hope, since the Medicare Advantage plan paid earlier for his care at Emory this year, that they will not balk at him going back to Emory, if we are able to get in the clinical there. Monday can't get here soon enough for me.
__________________
Linda, Al's wife, 75; dx MDS 5/2010; Vidaza 6/2010; ARRY614 & Sapacitabine clinical trials at Emory, no results, stopped 12/2011. Had BMB at NIH on 6/5/12, blasts 10-15% so he's not eligible for trial there. :eek Promacta trial, Tampa, blasts 25-30% 8/17/12 AML, trying Dacogen now and praying.
|